Quest’s new BRCA test may loosen Myriad’s hold on the genetic cancer testing market. The diagnostics firm is now selling tests for the two cancer genes that are linked to breast and ovarian cancer—BRCA1 and BRCA2—and for which Medicare pays around $3,400 when using Myriad’s version. Bloomberg reports that Quest plans on charging $2,500.